Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH

Postgraduate Medicine

Volumn 123, Issue 5, 2011, Pages 27-38

  Kordon, Andreas ^a   Stollhoff, Kirsten ^b   Niederkirchner, Käte ^c   Mattejat, Fritz ^d   Rettig, Klaus ^e   Schäuble, Barbara ^f  

^a Klinik fur Psychiatrie und Psychotherapie   (Germany)

^b Praxis für Kinderneurologie   (Germany)

^c Praxis für Kinder und Jugendmedizin ^*  (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e G E M Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH   (Germany)

^f Medical Affairs EMEA   (Germany)

Author keywords

ADHD; Children adolescents; OROSS methylphenidate; Transition

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; ADOLESCENT HEALTH; ADULT; AGGRESSION; ANOREXIA; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HEALTH CARE; CONCENTRATION LOSS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEALTH CARE NEED; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MUSCLE SPASM; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHARYNGITIS; PRESCHOOL CHILD; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; RHINITIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT INDICATION; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WEIGHT CHANGE; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE;

EID: 80052391342     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.09.2457     Document Type: Article

References (38)

1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248.
3. Polancszyk G, de Limas MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
4. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J Clin Psychiatry. 2004; 65(10):1301-1313.
5. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45(2):192-202.
6. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr. 2007;28(4):274-287.
7. Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9(3):481-498.
8. Johnson C, Marsh EJ. Families with children with ADHD: review and recommendations for future research. Clin Child Fam Psychol Rev. 2001;4(3):183-207.
9. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005;116(3):e364-e369.
10. McClure A, Prasad S, Poole L. Functional outcomes of children with attention deficit/hyperactivity disorder in the UK. Arch Dis Childhood. 2005;90:A48-A50.
11. Benkert D, Krause KH, Wasem J, Aidelsburger P. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment. DIMDI 2010; 108. http://portal.dimdi.de/de/hta/hta_berichte/hta267. Accessed December 21, 2010.
12. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines, CADDRA 2008. http://www.caddra.ca. Accessed December 16, 2009.
13. National Institute for Health and Clinical Excellence (NICE). Attentiondeficit/hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults, September 2008. http://www.nice.org.uk. Accessed December 16, 2009.
14. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother. 2006;7(15):2119-2139.
15. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003;17(2):117-131.
16. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry.2003;60(2):204-211.
17. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50-e62.
18. Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol. 2006;16(4):441-455.
19. Chou WJ, Chou MC, Tzang RF, et al. Better effi cacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin Neurosciences. 2009;63(2):167-175.
20. Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol Clin Exp. 2009;24(2):95-102.
21. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefi ts of long-acting stimulants. Eur Child Adolesc Psychiatry. 2010;19(4):325-340.
22. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, et al. The quality of life of children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2010;19(2):83-105.
23. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry. 1998;59(suppl 7):24-30.
24. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268.
25. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46(5):857-870.
26. Mattejat F, Jungmann J, Meusers M, et al. An inventory for assessing the quality of life of children and adolescents-a pilot study [in German]. Z Kinder Jugendpsychiatr Psychother. 1998;26(3):174-182.
27. Mattejat F, Simon B, König U, et al. Quality of life of children and adolescents with psychiatric disorders. Results of the 1st multicenter study with an inventory to assess the quality of life in children and adolescents [in German]. Zeitschrift für Kinder- und Jugendpsychiatrie. 2003;31(4):293-303.
28. Ehnis P, Trosse M, Remschmidt H. Life quality of children and adolescents in Germany. Results of a representative telephone survey. In: Remschmidt H, Belfer M, eds.16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, August 22-26, 2004. Stuttgart, Germany: Steinkopf; 2004:374.
29. Mattejat F, Remschmidt H. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) [The Inventory of Life Quality in Children and Adolescents (ILC)]. Bern, Switzerland: Verlag Hans Huber; 2006.
30. Jozefiak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U. Quality of life as reported by school children and their parents: a crosssectional survey. Health Qual of Life Outcomes. 2008;6:34.
31. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228-1231.
32. ® MPH. Results of a 3-week open-label study. Eur Child Adolesc Psychiatry. 2005;14(6):297-304.
33. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005;25(7):909-917.
34. Sasané R, Hodgkins P, Meijer W. Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Curr Med Res Opin. 2010;26(11):2565-2574.
35. Landgraf J, Abetz L, Ware JE. The CHQ User's Manual. Boston, MA: Health Institute; 1996.
36. Klassen AF, Miller A, Fine S. Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder. Child Care Health. 2006;32(4):397-406.
37. Pelham WE, Gnagy EM, Burrows-Maclean L. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107(6):E105.
38. Wolraich ML, Greenhill LL, Pelham W, et al; Concerta Study Group: Randomized, controlled trial of OROS methylphenidate once a day in children with attention deficit/hyperactivity disorder. Pediatrics. 2001;108(4):883-892.